Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
0 hedge funds and large institutions have $0 invested in Astria Therapeutics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 140 closing their positions.
99.02% less ownership
Funds ownership: 99.02% → 0% (-99%)
100% less funds holding
Funds holding: 141 → 0 (-141)
100% less capital invested
Capital invested by funds: $738M → $0 (-$738M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 140
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$84.9M |
| 2 |
BlackRock
New York
|
-$50.2M |
| 3 |
GCL
Glazer Capital LLC
New York
|
-$49.4M |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$44.9M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$31.4M |
ATXS Hedge Fund Activity: Q1 2026 in Review
0 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q1 2026, worth a combined $0 — down 100% from $738M a quarter earlier.
Sellers outnumbered buyers: 140 funds closed out of ATXS and 0 opened new positions — a net loss of 140 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Perceptive Advisors, exiting entirely with an estimated $84.9M sold.
- 0 institutional investors held Astria Therapeutics (ATXS) as of Q1 2026, down from 141 in Q4 2025.
- Funds reported $0 of Astria Therapeutics stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new Astria Therapeutics positions in Q1 2026 and 140 closed out, a net change of -140 holders.
- The largest Astria Therapeutics seller in Q1 2026 was Perceptive Advisors, an estimated $84.9M sold.
Based on aggregated 13F filings for Q1 2026.